Expedited Medicare Coverage for Breakthrough Devices via RAPID Pathway

On April 23, 2026, the Centers for Medicare & Medicaid Services (CMS) and the U.S. Food and Drug Administration (FDA) unveiled the Regulatory Alignment for Predictable and Immediate Device (RAPID) pathway. This initiative is designed to expedite Medicare coverage for breakthrough medical devices by minimizing delays between FDA market authorization and Medicare national coverage determinations. The program promotes a collaborative approach, ensuring CMS and FDA engage with device sponsors early to align regulatory compliance requirements.

The RAPID pathway's proposal will soon be published in the Federal Register, initiating a 60-day comment period before the final notice is issued. Though the exact implementation date is pending, this pathway will focus on breakthrough devices that meet specific criteria, including Class III and select Class II devices involved in the FDA’s Total Product Life Cycle Advisory Program (TAP).

Eligible devices must participate in an FDA-approved Investigational Device Exemption study, enrolling Medicare beneficiaries and emphasizing clinical health outcomes mutually agreed by CMS and FDA. High-risk breakthrough devices, such as Class III medical products for serious conditions prevalent in the Medicare population, stand to benefit significantly. The RAPID initiative aims to shorten the timeline for Medicare coverage post FDA authorization.

Class II devices in the TAP program may also benefit from this pathway. Early FDA engagement via TAP, coupled with CMS's early involvement in regulatory discussions, could enhance study designs beneficial to Medicare, thereby increasing the utility of RAPID for innovative diagnostics. Once FDA market authorization is secured, CMS intends to propose a National Coverage Determination on the same day, enabling Medicare payment initiation within approximately two months.

Despite the introduction of RAPID, existing processes, such as National Coverage Determination, continue. CMS has reaffirmed that FDA authorization and CMS coverage standards will remain unchanged. Past initiatives, like the Medicare Coverage for Innovative Technologies program, illustrate CMS's ongoing efforts to streamline breakthrough device coverage.

The RAPID pathway has garnered bipartisan support, aiming to provide certainty in coverage for breakthrough devices, alongside legislative initiatives like H.R. 5343. Industry stakeholders are optimistic about reducing approval-to-coverage timelines but are watchful of the proposal's specifics and its integration with existing systems.

As CMS proposes changes that might affect payment structures for breakthrough devices, industry professionals will monitor developments closely. This attention to detail will be crucial during the comment periods for the RAPID proposal and forthcoming Medicare payment system adjustments, ensuring comprehensive stakeholder feedback.